BCR and B-cell chronic lymphocytic leukemia: The dual inhibitor cerdulatinib, which targets both spleen tyrosine kinase (SYK, a BCR component) and JAK kinases, potently inhibits tumor growth and induces apoptosis in CLL cells at clinically feasible drug concentrations (120).